1. A dual αvβ1/αvβ6 integrin inhibitor Bexotegrast (PLN-74809) ameliorates organ injury and fibrogenesis in fibrotic kidney disease.
- Author
-
Mu Y, Liu J, Wu Q, Wang B, Hu T, Li Y, Yan X, Ma L, and Tan Z
- Subjects
- Animals, Male, Mice, Adenine analogs & derivatives, Adenine pharmacology, Antigens, Neoplasm metabolism, beta Catenin metabolism, beta Catenin antagonists & inhibitors, Disease Models, Animal, Focal Adhesion Kinase 1 metabolism, Focal Adhesion Kinase 1 antagonists & inhibitors, Kidney pathology, Kidney drug effects, Kidney metabolism, Kidney Diseases pathology, Kidney Diseases drug therapy, Kidney Diseases metabolism, Mice, Inbred C57BL, Proto-Oncogene Proteins c-akt metabolism, Receptors, Vitronectin antagonists & inhibitors, Receptors, Vitronectin metabolism, Signal Transduction drug effects, src-Family Kinases antagonists & inhibitors, src-Family Kinases metabolism, Ureteral Obstruction pathology, Ureteral Obstruction complications, Ureteral Obstruction drug therapy, Fibrosis, Integrins antagonists & inhibitors, Integrins metabolism
- Abstract
Chronic kidney disease (CKD) is a global public health problem, involving about 10% of the global population. Unfortunately, there are currently no effective drugs. Kidney fibrosis is the main pathology of CKD, where integrins play crucial roles in renal fibrogenesis. Recently, Bexotegrast (PLN-74809) as a dual integrin αvβ1/αvβ6 inhibitor could reduce the degree of lung fibrosis in patients with idiopathic pulmonary fibrosis. However, the role of PLN-74809 remains unclear in fibrotic kidney disease. Here, we have revealed that PLN-74809 administration dose-dependently delayed the progression of renal fibrosis in both adenine diet- and unilateral ureteral obstruction (UUO)-induced mice. Mechanistically, PLN-74809 targeted integrin αvβ1/αvβ6 to inhibit FAK/Src/Akt/β-catenin cascade in fibrotic kidneys. In summary, our results for the first time highlighted the αvβ1/αvβ6 inhibitor PLN-74809 exerted potential therapeutic against kidney fibrosis., Competing Interests: Declaration of competing interest The authors declare no competing interests., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF